O Shaughnessy Asset Management LLC lowered its holdings in Sanofi (NASDAQ:SNY - Free Report) by 12.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 115,257 shares of the company's stock after selling 16,977 shares during the quarter. O Shaughnessy Asset Management LLC's holdings in Sanofi were worth $5,559,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in Sanofi during the 4th quarter valued at approximately $135,933,000. Boston Partners lifted its position in Sanofi by 86.4% during the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after buying an additional 2,501,073 shares during the period. Magnetar Financial LLC boosted its holdings in shares of Sanofi by 104.3% during the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock valued at $161,103,000 after buying an additional 1,705,148 shares in the last quarter. DAVENPORT & Co LLC grew its position in shares of Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock worth $110,715,000 after buying an additional 664,455 shares during the period. Finally, Thrivent Financial for Lutherans increased its stake in shares of Sanofi by 36.0% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company's stock worth $93,774,000 after acquiring an additional 514,542 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors.
Sanofi Stock Up 1.2 %
NASDAQ SNY traded up $0.67 during mid-day trading on Thursday, reaching $54.62. The stock had a trading volume of 1,842,025 shares, compared to its average volume of 2,279,558. The company has a fifty day moving average price of $55.38 and a 200 day moving average price of $52.75. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a 1 year low of $45.22 and a 1 year high of $60.12. The stock has a market cap of $138.62 billion, a PE ratio of 21.94, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.
Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, research analysts expect that Sanofi will post 4.36 earnings per share for the current year.
Analyst Ratings Changes
A number of brokerages have weighed in on SNY. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. The Goldman Sachs Group assumed coverage on Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target on the stock. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Three analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $62.50.
Check Out Our Latest Stock Analysis on Sanofi
Sanofi Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
